Oncology Resource Group

We are closely tracking key presentations at SABCS, including Phase III EMBER-3 data on imlunestrant + abemaciclib for ER+ HER2- advanced breast cancer. This presentation at SABCS will give us critical insights into whether the combination benefit extends beyond patients with ESR1 mutations to the broader HR+ ITT population, clarifying how imlunestrant stacks up against elacestrant. 🔍 Why partner with us? Our deep analysis of clinical implications for imlunestrant and other drugs across breast cancer development will keep your teams ahead in drug development strategies. Stay informed. Stay ahead. Partner with us to unlock in-depth SABCS insights and gain the competitive edge you need. 📩 Contact Brittany Daggett, Erica Wescott, MSc., or Michael D. Reynolds today to learn more about our SABCS coverage! Unrivaled Insights, Unmatched Expertise #SABCS24 #oncology #breastcancer #competitivestrategy

What's next for IO? Subclasses with heightened activity over the past year included Cell Therapies and Bispecifics, while multi-subclass agents such as PD-(L)1 x VEGF mAbs have more recently been in the spotlight. These IO subclasses, as well as vaccine therapies, are predicted to experience sustained growth through 2025 and beyond. ONCrg analysts are here to discuss these topics and others with you. Comment below to join the conversation. Reach out to Brittany Daggett, Erica Wescott, MSc., or Michael D. Reynolds for more information about ONCrg’s Conference coverage. Unrivaled Insights, Unmatched Expertise #oncology #immunooncology #celltherapies #bispecifics #competitivestrategy

What's next for IO? Subclasses with heightened activity over the past year included Cell Therapies and Bispecifics, while multi-subclass agents such as PD-(L)1 x VEGF mAbs have more recently been in the spotlight. These IO subclasses, as well as vaccine therapies, are predicted to experience sustained growth through 2025 and beyond. ONCrg analysts are here to discuss these topics and others with you. Comment below to join the conversation. Reach out to Brittany Daggett, Erica Wescott, MSc., or Michael D. Reynolds for more information about ONCrg’s Conference coverage. Unrivaled Insights, Unmatched Expertise #oncology #immunooncology #celltherapies #bispecifics #competitivestrategy

ASH this year brings more opportunities—and challenges—than ever before, with several key sessions happening all at once. But we're here to support you! ONCrg's comprehensive conference prep and coverage helps you save time, optimize budgets, and gain valuable competitive intelligence. Ready to elevate your ASH experience? Connect with Erica Wescott, MSc., Brittany Daggett, or Michael D. Reynolds for a complimentary ONCrg ASH 2024 planner. Unrivaled Insights, Unmatched Expertise #ASH24 #oncology #HematologicCancers #HemeOnc #celltherapies #competitivestrategy

Support your team with the insight they need to make decisions. Stay competitive with Oncology Resource Group's Pipeline Strategies Reports, which are now refreshed for Q3 2024. Breast cancer drug development is complex, with 64 registrational trials underway. At ONCrg, we keep a close eye on all the latest updates, big or small, so your team can save time and stay on top of the competition. We help you reliably track and interpret competitor activities, making sure you don't get left behind. Contact Brittany Daggett or Erica Wescott, MSc. to see more of our ONCrg Pipeline Strategies: Breast Cancer report, or for other solid tumors, hematologic malignancies, and MOAs. Unrivaled Insights, Unmatched Expertise #Oncology #CompetitiveStrategy #BreastCancerAwareness #competitivelandscape

🚨 Need coverage support for SITC 2024 in Houston on Nov 8th-10th? 🚨 Planning for major conferences like #SITC24 can be challenging – from navigating frustrating online programs to keeping up with evolving timelines for title releases - and that's where ONCrg steps in! With years of experience analyzing and attending these conferences, we ensure you stay ahead of the curve. 📈 We monitor and highlight the most impactful data to build ONCrg's exclusive conference planner. Our comprehensive conference prep and coverage helps you save time, optimize budgets, and gain valuable competitive intelligence. Ready to elevate your SITC experience? Reach out to Brittany Daggett, Erica Wescott, MSc., or Michael D. Reynolds today! #SITC2024 #oncology #competitivestrategy #immunooncology #pharmaCI

This October, as we observe Breast Cancer Awareness Month, let's honor survivors, remember those we've lost, and advocate for early detection - a crucial step in improving outcomes. Education and awareness can save lives. 💝 #BreatCancerAwarenessMonth #SupportAndAwareness

Support your team with the insight they need to make decisions. Stay competitive with Oncology Resource Group's Pipeline Strategies Reports. Drug development for ovarian cancer has been shifting from IO and PARP inhibitors to ADCs. ONCrg stays on top of the news, big and small, to save your team time and to ensure competitor activities are reliably interpreted. Contact Brittany Daggett or Erica Wescott, MSc. to see more of our ONCrg Pipeline Strategies: Ovarian Cancer report, or for other solid tumors, hematologic malignancies, and MOAs. Unrivaled Insights, Unmatched Expertise #Oncology #CompetitiveStrategy #OvarianCancerAwareness #competitivelandscape

Our team is excited to attend WCLC 2024 in San Diego! We're particularly keen to cover groundbreaking data, including that from Phase III HARMONi-2. This will expand on the topline disclosed in May 2024: the primary endpoint (PFS) was met in this head-to-head Phase III trial, marking the first victory over pembrolizumab. Ivonescimab + platinum CT has been approved in China for EGFR TKI-R/R EGFRm+ NSCLC, becoming the world’s first approved IO x anti-angiogenesis bispecific drug. For more details on our NSCLC, SCLC, ADCs, and Late Stage IO conference coverage, reach out to Brittany Daggett or Erica Wescott, MSc. #WCLC24 #IASLC2024 #lungcancer #NSCLC #SCLC #oncology #competitiveintelligence

Equip your team with the insight they need to make decisions. Stay competitive with Oncology Resource Group's Pipeline Strategies Reports. Endometrial cancer is evolving fast with a flurry of new approvals, including two this month. ONCrg stays on top of the news, big and small, to save you time. Contact Brittany Daggett to see more of our ONCrg Pipeline Strategies: Endometrial Cancer report, or for other solid tumors, hematologic malignancies, and MOAs. Unrivaled Insights, Unmatched Expertise #oncology #competitivestrategy #endometrialcancer #competitivelandscape